Author:
Montorsi Francesco,Scuderi Simone,Briganti Alberto,Gandaglia Giorgio
Reference3 articles.
1. Powell K, Burns MC, Prasad V. Relugolix: five reasons why the US Food and Drug Administration should have exercised restraint. Eur Urol. 2023;83:101–2.
2. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer;Shore;N Engl J Med,2020
3. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology; 2022. https://uroweb.org/guidelines/prostate-cancer.